Engflag

Ziac

Quick links to important sections

Ziac

Ziac_EN

Method of action: Antianginal, Antiarrhythmic, Antihypertensive, Beta Blocking Agents, Beta-Blocker, Diuretic, Hypotensive

Treatment option: Hypertension

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ziac

What is Ziac? An Overview of Identity and Purpose

Property Description
Active Ingredients Bisoprolol Fumarate, Hydrochlorothiazide
Form Fixed-Dose Combination (FDC) Tablet
Pharmacological Class Adrenergic Beta-Blocker and Thiazide Diuretic
Common Purpose Management of high blood pressure (hypertension)
Origin Synthetic Drug

What Type of Medicine is Ziac (Bisoprolol/Hydrochlorothiazide)?

Ziac is a prescription-only medication classified as a synthetic Antihypertensive Agent, clinically recognized for its role in managing high blood pressure (hypertension). It is defined as a Combination Product containing two distinct active ingredients belonging to two major pharmacological classes. Bisoprolol Fumarate is a Beta-1 Selective Adrenergic Blocking Agent, and Hydrochlorothiazide is a Thiazide Diuretic. This means the medicine works by targeting two different, yet complementary, physiological mechanisms related to blood pressure regulation.

This cardiovascular medicine integrates the beta1-selective blocker component, Bisoprolol Fumarate, with the diuretic component, Hydrochlorothiazide (HCTZ), which is derived from the benzothiadiazine class. The use of this specific FDC is often a standard step when initiating combination therapy for adults. The antihypertensive effects of these agents are additive.

Ziac's Composition and Combination Form

Ziac is formulated as a Fixed-Dose Combination (FDC) combination tablet intended for oral administration, precisely combining the two active compounds within a single pharmaceutical preparation. This specialized dosage form is a differentiating factor, offering the benefit of dual-action therapy in one pill. The combination of a highly selective beta-blocker with a diuretic provides a distinct and widely accepted strategy in chronic disease management.

This format helps simplify treatment for chronic conditions. Instead of requiring a patient to take separate tablets of Bisoprolol monotherapy and Hydrochlorothiazide monotherapy, the combination tablet reduces the overall pill burden. This design, which uses pharmaceutical excipients for the tablet base, is fundamentally intended to support patient adherence, particularly in long-term therapy for individuals managing hypertension.

General Purpose: Why is This Combination Used?

The general purpose of the Bisoprolol/Hydrochlorothiazide combination is to provide powerful, sustained moderation of systemic pressure by influencing two primary areas of the cardiovascular system. This is achieved through the synergistic effect of the components: the Bisoprolol works to control the heart's workload by decreasing cardiac output, while the Hydrochlorothiazide component facilitates volume reduction through increased water and sodium excretion.

Hydrochlorothiazide works by causing the kidneys to get rid of unneeded water and salt from the body into the urine. This dual physiological action cooperates to normalize high systemic pressure. This normalization is the foundational general benefit of the medication, acting to help protect the body, particularly the sensitive vascular system and associated organs, from the prolonged stress associated with chronic, uncontrolled high blood pressure.

What side effects are possible with Ziac?

Possible Side Effects and Safety Information

Ziac's official safety profile is defined by adverse reactions associated with its two components, Bisoprolol (beta-blocker) and Hydrochlorothiazide (diuretic), as classified in regulatory documents.

Adverse Reaction Scope

Classification Examples of Effects (Strictly Regulatory)
Common Effects Fatigue, headache, dizziness, slow heart rate (bradycardia), and gastrointestinal disturbances

. | | Uncommon/Rare Effects | Sleep disturbances, muscle weakness, increases in hepatic enzymes, and sexual dysfunction. |

Adverse reactions are grouped by System-Organ Class, affecting the Nervous System, Cardiac function, Gastrointestinal tract, and Metabolism and Nutrition (risk of electrolyte imbalance).

Serious Safety Constraints

The label documents serious adverse reactions that require clinical attention, including the potential for severe bradycardia, clinically significant electrolyte imbalance (such as hypokalemia), and the exacerbation of pre-existing cardiac failure. The Hydrochlorothiazide component is also associated with rare effects like acute angle-closure glaucoma and severe cutaneous reactions.

Time-related patterns note that initial effects like fatigue and dizziness may be more frequent at the start of treatment or with dose adjustments. Official regulatory documents list absolute contraindications, meaning the drug must not be used in patients with anuria, overt cardiac failure, cardiogenic shock, or severe AV block.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose of Ziac (Bisoprolol/Hydrochlorothiazide) is officially documented to affect the cardiovascular and metabolic systems. Potential overdose manifestations resulting from the beta-blocker component (Bisoprolol) include bradycardia (abnormally slow heart rate), hypotension (low blood pressure), and symptoms of congestive heart failure exacerbation, along with risk of bronchospasm. Overdose effects from the diuretic component (Hydrochlorothiazide) can lead to severe electrolyte depletion, notably hypokalemia and dehydration, which may precipitate dangerous cardiac arrhythmias or metabolic alkalosis. Both components contribute to the risk of severe, life-threatening outcomes such as Cardiogenic Shock and circulatory collapse.

Immediate Action Mandated by Regulators

Regulatory documents state that any suspected overdose of Ziac requires seeking immediate medical attention. Urgent medical help is necessary when symptoms include profound hypotension, severe bradycardia, or signs of life-threatening systemic compromise. In all cases, contact with a Poison Control Center or emergency services is mandated.

Management is restricted to symptomatic and supportive treatment, as no specific antidote is known for Bisoprolol. Official procedures include correction of fluid and electrolyte imbalances, administration of specific pharmacological agents for beta-blockade reversal, and continuous hospital monitoring of vital signs, ECG, and serum electrolytes.

Therapeutic Uses of Ziac

What Ziac Treats: Main Uses and Benefits

Ziac (bisoprolol and hydrochlorothiazide) is a combination prescription drug indicated for the treatment of high blood pressure. This medication is used as a component of a comprehensive plan to help support blood pressure goals in adults. The primary clinical scenario for its use is the management of essential hypertension. High blood pressure is a condition that, if not addressed, may contribute to the risk of serious health issues.

This medication is intended to provide therapeutic assistance by helping to reduce blood pressure. Using a combination drug may also offer the convenience of a single tablet for the patient.

Quick Fact: Therapeutic assistance for High Blood Pressure

Eligibility and Restrictions for Use

Official Eligibility and Contraindications for Ziac

Ziac (bisoprolol fumarate and hydrochlorothiazide) is contraindicated and must not be used by specific populations due to the risk of serious adverse health effects, as defined by regulatory documents. The primary groups excluded are those with certain severe, pre-existing conditions:

  • Cardiovascular Conditions: Patients with cardiogenic shock, overt cardiac failure, second- or third-degree atrioventricular (AV) block, or marked sinus bradycardia should not use this medication.
  • Hypersensitivity: Use is prohibited for individuals with a known allergy to either bisoprolol, hydrochlorothiazide, or any other sulfonamide-derived drugs.
  • Renal Function: Patients with anuria (inability to urinate) are absolutely excluded.

Special Considerations and Not Recommended Use:

  • Pediatric Population: Safety and effectiveness have not been established in patients younger than 18 years old; therefore, use in this population is not recommended.
  • Pregnancy and Lactation: Use during pregnancy is generally advised only if the potential benefit justifies the risk to the fetus. Since hydrochlorothiazide is excreted in human milk, a decision must be made to discontinue breastfeeding or discontinue the drug, based on the drug's importance to the mother.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Ziac (Bisoprolol/Hydrochlorothiazide) is defined by distinct pharmacodynamic and pharmacokinetic interactions documented in regulatory labeling.

Documented Interaction Patterns

Classification Interacting Agents Official Regulatory Statement
Cardiovascular Reinforcement Rate-Limiting Calcium Channel Blockers (e.g., Verapamil, Diltiazem) May result in enhanced negative cardiac effects, including additive reduction in heart rate and contractility.
Efficacy Antagonism Nonsteroidal Anti-inflammatory Drugs (NSAIDs) Cause a documented reduction of the antihypertensive and diuretic effects.
Exposure Modification Rifampin (Enzyme Inducer) Reduces the plasma concentration of the Bisoprolol component, decreasing its therapeutic effect.
Absorption Constraint Aluminum-containing Antacids Decrease Bisoprolol serum levels via inhibition of gastrointestinal absorption, requiring separation of administration.

The profile also notes that the Hydrochlorothiazide component may interfere with Antidiabetic Agents by raising blood glucose, while the Bisoprolol component may mask signs of hypoglycemia. The combination with Corticosteroids increases the risk of hypokalemia. The bioavailability of Ziac is not affected by food, but Alcohol (Ethanol) has an additive effect in lowering blood pressure.

Mechanism of Action

Ziac is a combination medication containing bisoprolol (a beta1-selective adrenoceptor blocker) and hydrochlorothiazide (a thiazide diuretic), which act through distinct mechanistic domains to induce combined physiological consequences.

Cardiac beta1-Adrenoceptor Blockade

This domain centers on the beta1-adrenergic receptors, primarily in the myocardium, and involves bisoprolol competitively binding to them. This action modifies the signaling pathway activated by the sympathetic nervous system, leading to a diminished response to endogenous catecholamines. The resulting physiological consequence is a decrease in both heart rate (negative chronotropy) and the force of heart muscle contraction (negative inotropy).

Renal Electrolyte and Fluid Modulation

This domain involves the action of hydrochlorothiazide (HCTZ) within the renal tubules, specifically targeting and inhibiting the Na^+- Cl^- cotransporter in the distal convoluted tubule. This inhibition initiates a mechanistic cascade that reduces the reabsorption of sodium and chloride ions, promoting the increased excretion of Na^+, Cl^-, and water. This sequence leads to natriuresis, diuresis, and reduced overall intravascular fluid volume.

Renin-Angiotensin System Modulation

Both components influence the systemic renin-angiotensin system (RAS). Bisoprolol indirectly acts on the RAS by blocking beta1-receptors on the juxtaglomerular cells, thereby limiting the stimulation of renin release. HCTZ’s effect on plasma volume and electrolytes also modulates this system. This combined action influences systemic pathway activity.

Dosage and Administration Information

How Ziac is Used: Administration Guidelines

Ziac (bisoprolol fumarate and hydrochlorothiazide) is a Fixed-Dose Combination (FDC) tablet indicated for oral administration. The use of this medication is defined by a structured, once-daily regimen with specific guidelines for dosing adjustments and discontinuation.

Administration Protocol

Feature Instruction Summary
Route of Administration Oral administration (by mouth).
Available Strengths 2.5 mg/6.25 mg, 5 mg/6.25 mg, and 10 mg/6.25 mg (Bisoprolol/HCTZ).
Dosing Schedule Once daily. Initial Dose: One 2.5 mg/6.25 mg tablet once daily.
Maximum Dose The maximum recommended dose is 20 mg bisoprolol / 12.5 mg hydrochlorothiazide once daily.
Titration/Adjustment Dose adjustments, if necessary, should be carried out at intervals of approximately 14 days.
Timing & Food Intake Recommended to take the tablet in the morning, and it may be taken with or without food.
Tablet Handling The tablet must be swallowed whole with liquid and not chewed.

Usage Guidance for Specific Populations

There are specific recommendations for certain groups:

  • Older Adults: Dosage adjustment based solely on age is not usually necessary, unless the patient has significant hepatic or renal dysfunction.
  • Renal/Hepatic Impairment: Caution must be used during the dosing and titration of patients with renal dysfunction or hepatic impairment. Dose adjustment may be necessary due to the potential for cumulative effects of the components.
  • Pediatric Patients: There is no pediatric experience for this combination product, and safety and effectiveness have not been established in patients under 18 years of age.

Discontinuation and Missed Doses

If therapy is to be stopped, the protocol is that withdrawal of Ziac should be achieved gradually over a period of about 2 weeks. If a dose is missed, the instruction is to take the dose as soon as remembered; however, if it is almost time for the next scheduled dose, the missed dose should be skipped, and the patient should resume the regular schedule. Doses should not be doubled to compensate for a missed dose.

Recent Clinical Evidence

Overview of Ziac Clinical Evidence

Ziac is a fixed-dose combination of the beta-blocker bisoprolol fumarate and the thiazide diuretic hydrochlorothiazide (HCTZ), primarily studied for the management of hypertension (high blood pressure). Clinical trials investigate how this combination affects blood pressure and heart rate compared to its individual components or placebo.

Efficacy and Response in Hypertension

Research has explored the antihypertensive effects of the bisoprolol/HCTZ combination, particularly at low fixed doses. A systematic review and meta-analysis focusing on Stage I and II hypertension observed that this combination significantly reduced both systolic BP (SBP) and diastolic BP (DBP) when compared to control groups.

  • Blood Pressure Control: Studies report that the fixed combination can achieve adequate blood pressure control in a substantial percentage of patients with mild-to-moderate hypertension. The combination leverages the complementary actions of the two drug classes, which may lead to a more pronounced blood pressure reduction.
  • Heart Rate: Bisoprolol is known for its selective action on beta1-adrenergic receptors. Clinical trials have consistently shown a reduction in resting and exercise heart rate in patients receiving the combination therapy.

Safety Profile and Electrolyte Balance

Clinical trials have examined the safety profile and metabolic effects of the fixed-dose combination, particularly noting the impact of combining a beta-blocker with a diuretic:

Study Focus Key Observation
Electrolyte Levels The fixed combination's low HCTZ dose (typically 6.25 mg) resulted in a significantly lower incidence of hypokalemia (low potassium) compared to higher HCTZ monotherapy doses (e.g., 25 mg).
Tolerability In clinical trials, the reported incidence of common side effects, such as dizziness and fatigue, was generally comparable to that of placebo.

These findings suggest that the low-dose combination may minimize certain dose-dependent metabolic disturbances associated with higher diuretic doses alone.

Frequently Asked Questions (FAQ)

Common questions about Ziac (FAQ)

Q: Does it make you sleepy?

A: Official regulatory documents and product information list certain central nervous system (CNS) effects as potential side effects of Ziac. These effects can include dizziness, somnolence (the medical term for sleepiness), or fatigue. The full safety information provided in the product label or by the regulatory agency lists all known effects.

Q: Can children 2 years old use it?

A: The official product labeling for Ziac specifies the approved age range for which the drug has established safety and effectiveness. The official information indicates the safety and effectiveness have not been established or approved for age groups outside of the officially authorized patient population, such as children 2 years old.

How should Ziac be stored and disposed of?

How to Store and Dispose of Ziac

Ziac (bisoprolol fumarate and hydrochlorothiazide) tablets must be stored according to regulatory requirements to maintain product quality and stability.

  • Storage Temperature: Store the tablets at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F).
  • Environmental Protection: Keep the container tightly closed and store in a dry place away from excess moisture, heat, and direct light. The product must also be protected from freezing.
  • Child Safety: It is mandatory to store Ziac out of the reach of children and pets.

For disposal, unused or expired Ziac should not be flushed down a toilet or poured down a drain. The official instruction is to utilize a drug take-back program or follow regulatory guidance for safe household disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagArgentina

flagChile

flagEcuador

flagGreece

flagPeru

flagPhilippines

flagUSA

Equivalent of Ziac found in:

A-Z Index: